Earnings summaries and quarterly performance for Aura Biosciences.
Executive leadership at Aura Biosciences.
Elisabet de los Pinos
Detailed
Chief Executive Officer and President
CEO
Amy Elazzouzi
Detailed
Senior Vice President, Finance; Interim Principal Financial Officer and Interim Principal Accounting Officer
Conor Kilroy
Detailed
Chief Legal Officer and Secretary
J. Jill Hopkins
Detailed
Chief Medical Officer and President of Research and Development
Mark Plavsic
Detailed
Chief Technology Officer
Board of directors at Aura Biosciences.
Research analysts covering Aura Biosciences.
Recent press releases and 8-K filings for AURA.
Aura Biosciences Provides Update on Bel-sar Clinical Development and 2026 Catalysts
AURA
New Projects/Investments
Guidance Update
- Aura Biosciences is developing Bel-sar, a novel Virus-like Drug Conjugate, with a Phase III trial ongoing for early-stage choroidal melanoma.
- Enrollment for the Phase III CoMpass study in choroidal melanoma is projected to complete in 2026, with top-line data expected in Q4 2027.
- The company anticipates three-month data in 2026 from four cohorts in its bladder cancer program, which is positioned as a frontline neoadjuvant treatment.
- Additionally, proof-of-concept study readouts for Bel-sar in other ocular indications, including metastatic and ocular surface cancers, are expected in 2026.
- Bel-sar is highlighted for its vision-preserving capabilities and favorable safety profile in early choroidal melanoma, addressing an unmet need with no current competition in this specific market.
4 days ago
Aura Biosciences Reports Q3 2025 Financial Results and Provides Pipeline Updates
AURA
Earnings
Guidance Update
New Projects/Investments
- Aura Biosciences reported a net loss of $26.1 million for the third quarter ended September 30, 2025, with research and development expenses rising to $22.2 million.
- The company's cash, cash equivalents, and marketable securities totaled $161.9 million as of September 30, 2025, which is expected to fund operations into the first half of 2027.
- Enrollment for the Phase 3 CoMpass trial in early choroidal melanoma is now expected to complete in 2026, with topline data anticipated in Q4 2027 for the 15-month primary endpoint.
- The Phase 1b/2 trial in NMIBC remains on track for data in mid-2026, and early proof of concept data for both the Phase 2 choroidal metastases and Phase 1 ocular surface cancers trials are expected in 2026.
Nov 13, 2025, 12:05 PM
Aura Biosciences Reports Q3 2025 Financial Results and Provides Clinical Trial Guidance
AURA
Earnings
Guidance Update
New Projects/Investments
- Aura Biosciences reported a net loss of $26.1 million for the three months ended September 30, 2025, with research and development expenses at $22.2 million.
- As of September 30, 2025, the company held $161.9 million in cash and cash equivalents and marketable securities, which is expected to fund operations into the first half of 2027.
- Enrollment for the Phase 3 CoMpass trial in early choroidal melanoma is projected to complete in 2026, with topline data for the 15-month primary endpoint anticipated in Q4 2027.
- Initial three-month clinical data from the Phase 1b/2 trial in non-muscle invasive bladder cancer (NMIBC) is expected in mid-2026.
- Early proof of concept data for the Phase 2 trial in metastases to the choroid and the Phase 1 trial in cancers of the ocular surface are both expected in 2026.
Nov 13, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more